| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of General Neurology, Hertie Institute for Clinical Brain Research (W. Wick, J.P. Steinbach, J. Dichgans, and M. Weller), and Departments of Neuroradiology (W.M. Küker) and Radiation Oncology (M. Bamberg), University of Tübingen Medical School, Germany.
Address correspondence and reprint requests to Dr. Wolfgang Wick, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany; e-mail: wolfgang.wick{at}uni-tuebingen.de
Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles. Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-free survival was 5 months. The progression-free survival at 6 months was 48%.
Received September 8, 2003. Accepted in final form January 29, 2004.
This article has been cited by other articles:
|
|
 |
|
  W. Wick, M. Platten, and M. Weller New (alternative) temozolomide regimens for the treatment of glioma Neuro-oncol, January 1, 2009; 11(1): 69 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-K. Bracht, P. Wen, J. A. Meyerhardt, M. H. Kulke, J. L. Hornick, M. Redston, D. C. LaFrankie, P. M. Black, S. Kesari, A. Norden, et al. DNA Repair Enzyme Expression and Differential Response to Temozolomide in a Patient With Both Glioblastoma and Metastatic Pancreatic Neuroendocrine Tumor J. Clin. Oncol., October 10, 2008; 26(29): 4843 - 4844. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, and M. R. Gilbert Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity J. Clin. Oncol., September 1, 2008; 26(25): 4189 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Beier, S. Rohrl, D. R. Pillai, S. Schwarz, L. A. Kunz-Schughart, P. Leukel, M. Proescholdt, A. Brawanski, U. Bogdahn, A. Trampe-Kieslich, et al. Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma Cancer Res., July 15, 2008; 68(14): 5706 - 5715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Filippini, C. Falcone, A. Boiardi, G. Broggi, M. G. Bruzzone, D. Caldiroli, R. Farina, M. Farinotti, L. Fariselli, G. Finocchiaro, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma Neuro-oncol, February 1, 2008; 10(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nagane, K. Kobayashi, A. Ohnishi, S. Shimizu, and Y. Shiokawa Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide Jpn. J. Clin. Oncol., December 21, 2007; (2007) hym132v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wick, J. Felsberg, J. P. Steinbach, U. Herrlinger, M. Platten, B. Blaschke, R. Meyermann, G. Reifenberger, M. Weller, and W. Wick Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma J. Clin. Oncol., August 1, 2007; 25(22): 3357 - 3361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al. Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hau, D. Koch, T. Hundsberger, E. Marg, B. Bauer, R. Rudolph, M. Rauch, A. Brenner, P. Rieckmann, J. Schuth, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology, February 27, 2007; 68(9): 688 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Herrlinger, J. Rieger, D. Koch, S. Loeser, B. Blaschke, R.-D. Kortmann, J. P. Steinbach, T. Hundsberger, W. Wick, R. Meyermann, et al. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03 J. Clin. Oncol., September 20, 2006; 24(27): 4412 - 4417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Wong, A. A. Brandes, and A. Tosoni Is protracted low-dose temozolomide feasible in glioma patients? Neurology, August 8, 2006; 67(3): 543 - 544. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tosoni, G. Cavallo, M. Ermani, L. Scopece, E. Franceschi, C. Ghimenton, M. Gardiman, L. Pasetto, V. Blatt, and A. A. Brandes Is protracted low-dose temozolomide feasible in glioma patients? Neurology, February 14, 2006; 66(3): 427 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wick and M. Weller How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience J. Clin. Oncol., June 20, 2005; 23(18): 4235 - 4236. [Full Text] [PDF]
|
|
|
|
|
|
E. T. Wong, L. E. Abrey, R. H. Enting, A. Demopoulos, and L. M. DeAngelis Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Neurology, March 8, 2005; 64(5): 934 - 934. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
